Brief: Allovir Reports Third Quarter 2022 Financial Results
03/11/2022 11:15
Nov 3 (Reuters) - Allovir Inc ALVR.O :
* ALLOVIR REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
* Q3 LOSS PER SHARE $0.50
* ALLOVIR-FINAL TOPLINE DATA FROM POSOLEUCEL PHASE 2 STUDY
FOR
TREATMENT OF BK VIREMIA IN KIDNEY TRANSPLANT PATIENTS ON TRACK
TO BE RELEASED IN Q1 2023
Source text for Eikon: ID:nBwdB2V7a
Further company coverage: ALVR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kalaris Therapeutics
See all newsKalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Kalaris Therapeutics Q2 net loss narrows on lower administrative costs
Kalaris Therapeutics Inc expected to post a loss of 49 cents a share - Earnings Preview
Kalaris Therapeutics posts smaller-than-expected Q1 net loss
Brief: Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million